Test before-surgery cancer treatment for breast tumors with DNA repair gene changes
Treatments studied
Part of Cancer clinical trials.
This trial tests a combination of medications given before surgery (neoadjuvant therapy) for early breast cancer. It is designed for tumors with certain “DNA repair” gene mutations and aims to improve treatment results while shrinking or controlling the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your breast cancer is Her-2 negative (not driven by the Her-2 protein).
- Your cancer has not spread to distant organs (no distant metastasis).
- You have certain gene mutations linked to DNA repair—such as BRCA1, BRCA2, PALB2, or several related genes (like ATM or CHEK2).
- Your disease stage fits common early ranges (for example, some lymph node involvement, but not distant spread).
- You are well enough to function normally day-to-day (performance status 0 to 1).
- You are not pregnant or breastfeeding, and you can use birth control if needed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of targeted drugs and chemotherapy before surgery for HER2-positive breast cancer. It aims to see if this approach can shrink or eliminate the tumor, making surgery more effective.
This trial studies breast cancer tumors to see how specific gene changes and DNA damage patterns relate to the cancer in people with HER2-low disease. It may help doctors better predict which patients could benefit from treatments that target these pathways.
This study tests a combination of two drugs – fluzoparib (a PARP inhibitor) and camrelizumab (an immunotherapy) – given before surgery for early-stage or locally advanced HER2-negative breast cancer in people with an inherited BRCA mutation. The goal is to see if this treatment can shrink the tumor and improve outcomes.
This trial tests a combination of two oral medications (HRS-1167 and famitinib) with or without an immunotherapy drug (camrelizumab) before surgery for women with a BRCA gene mutation and HER2-negative breast cancer. It aims to see if these drugs can shrink tumors before surgery.
This trial tests different combinations of targeted therapy and chemotherapy before surgery for HER2-positive breast cancer. It uses a special PET scan to see how well the treatment is working and to help choose the best treatment plan for each person.
This trial tests a new precision therapy given before surgery for women with a specific type of HR-positive breast cancer. It aims to see if this treatment can improve outcomes.
Hear when a new HER 2 Negative Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.